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Background: Type 2 diabetes mellitus (T2D) is highly prevalent in Middle-Eastern and North African Arab populations,
but the molecular basis for this susceptibility is unknown. Altered DNA methylation levels were reported in insulin-
secreting and responding tissues, but whether methylation in accessible tissues such as peripheral blood is associated
with T2D risk remains an open question. Age-related alteration of DNA methylation level was reported in certain
methylation sites, but no association with T2D has been shown. Here we report on a population-based study of 929
men and women representing the East Jerusalem Palestinian (EJP) Arab population and compare with the findings
among Israeli Ashkenazi Jews. This is the first reported epigenetic study of an Arab population with a characteristic
high prevalence of T2D.
Results: We found that DNA methylation of a prespecified regulatory site in peripheral blood leukocytes (PBLs) is
associated with impaired glucose metabolism and T2D independent of sex, body mass index, and white blood cell
composition. This CpG site (Chr16: 53,809,231-2; hg19) is located in a region within an intron of the FTO gene,
suspected to serve as a tissue-specific enhancer. The association between PBL hypomethylation and T2D varied by
age, revealing differential patterns of methylation aging in healthy and diabetic individuals and between ethnic
groups: T2D patients displayed prematurely low methylation levels, and this hypomethylation was greater and
occurred earlier in life among Palestinian Arabs than Ashkenazi Jews.
Conclusions: Our study suggests that premature DNA methylation aging is associated with increased risk of T2D.
These findings should stimulate the search for more such sites and may pave the way to improved T2D risk
prediction within and between human populations.
Keywords: Type 2 diabetes, DNA methylation, Epigenetic aging, Leukocytes, East Jerusalem Palestinians, Ashkenazi
Jews, Population epigenetics, Ethnic groupsBackground
The prevalence of type 2 diabetes mellitus (T2D) is
particularly high in Arab populations; six of the top
ten ranked countries by diabetes prevalence are Arab
Middle-Eastern countries, the prevalence in Middle-
Eastern and North African countries being 64% higher
than in European countries [1-5]. Among Arabs in
Israel, the prevalence of T2D was reported to be almost
twofold higher and the age of onset 11 years earlier than
among Jews of same geographic area and age (average* Correspondence: asafh@ekmd.huji.ac.il
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unless otherwise stated.onset at age 57 vs. 68 years in Arabs and Jews, respect-
ively) [6]. The molecular basis for this higher prevalence
and earlier age of onset is unknown.
Altered DNA methylation levels were reported in
insulin-secreting and insulin-responding tissues of T2D
patients [7-10], but whether methylation in peripheral
blood leukocytes (PBLs) is associated with T2D risk
remains an open question. We previously reported a
genome-wide screen of DNA methylation differences
among T2D cases and controls in the Ashkenazi Jew
(AsJ) population. This methylation site in the first intron
of the FTO gene showed, in the context of a longitudinal
case–control design nested in a cohort, evidence for
T2D-related hypomethylation in PBLs of healthy youngl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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independently of the effects of risk sequence alleles [11].
Further investigation suggested some clues as to the
possible function of this methylation site. First, it is
located only 16 bases from SNP rs1121980 that was
repeatedly found to be associated with T2D and obesity
[12-14]. Second, based on its intermediate methylation
level and histone modification marks, this site may be
linked to regulation of gene expression since it resides
within a putative tissue-specific enhancer. Moreover, it
resides within a perfect binding motif of USF1/2 tran-
scription activators that play an important role in the
regulation of glucose and lipid metabolism in response
to insulin, as well as participating in beta-cell develop-
ment [15,16]. Third, in spite of the established associ-
ation between FTO alleles and obesity, our analysis
indicates no association between methylation at this site
and body mass [11]. These results are in line with the
reported residual association of SNPs in the region with
T2D independent of obesity [17,18]. Finally, Smemo
et al. recently reported evidence suggesting that this
region acts as an enhancer in the human brain and
that it may directly interact with and control the
expression of the IRX3 promoter, which in turn regu-
lates body mass and composition [19].
Here we investigate a population-based sample drawn
from the East Jerusalem Palestinian (EJP) Arab popula-
tion. The results reveal a significant association between
PBL DNA hypomethylation and T2D that varied by age,
suggesting differential patterns of methylation aging in
healthy and diabetic individuals. This is the first reported
epigenetic marker to be associated with T2D in any high
T2D prevalence Arab population.
Results
Characteristics of the EJP study sample are shown in
Table 1. The Palestinian sample comprised 929 individ-
uals (53% men) of mean age 51.8 years (age range at
examination 25.7 to 77.4 years). In accordance withTable 1 Characteristics of the EJP and Ashkenazi Jewish study
Study design
and sample






PS-EJP Group 1: normal GM 295 31.8 51.2 4
PS-EJP Group 2: borderline GM 173 18.6 59.5 4
PS-EJP Group 3: IGM 194 20.9 50.5 5
PS-EJP Group 4: T2D 267 28.7 52.8 6
PS-EJP Groups 1 + 2 468 50.4 54.3 4
PS-EJP Groups 3 + 4 461 49.6 51.8 5
CC-AsJ No diabetes 348 55.3 41.1 5
CC-AsJ T2D 281 44.7 47.7 6
EJP: East Jerusalem Palestinian; PS: Cross-sectional population-based sample; GM: G
AsJ: Ashkenazi Jewish; CC: Cross-sectional case–control.previous reports of high T2D prevalence in Arab pop-
ulations [1-6], 28.7% of the EJP participants were fully
diabetic, and a further 20.9% had impaired glucose
metabolism (IGM). Age was, as expected, strongly as-
sociated with diabetes status, increasing monotonically
from a mean of 44.1 years in the normal GM group
to 60.3 years in the T2D group. Body mass index
(BMI) increased monotonically across the four diabetes
categories from 27.8 kg/m2 in the normal GM group
to 31.4 kg/m2 in the T2D group.Association of methylation with T2D prevalence in the
EJP sample
Multiple factors may influence methylation level. We
assessed the methylation association with T2D taking
account of potential confounders and effect modifiers
including age, sex, BMI, and white blood cell compos-
ition (lymphocyte to granulocyte ratio).
We examined these potential effects using two dif-
ferent definitions of the disease status: first, we defined
the outcome as T2D categories 3 and 4 (IGM + T2D,
n = 461) vs. categories 1 and 2 (normal GM + border-
line GM, n = 468), and second, we restricted the com-
parison to category 4 (T2D patients, n = 267) vs. category
1 (normal GM subjects, n = 295). For each of the two
comparisons, we constructed three models: model 1
included methylation of the FTO site and age adjustment
using linear and quadratic terms for age; model 2 tested
for interaction and included the model 1 variables in
addition to a multiplicative term of linear age and me-
thylation; and model 3 included additional adjustment
for BMI, sex, and the lymphocyte to granulocyte ratio
(Table 2). Differences in PBL methylation could result
from altered methylation of lymphocytes or granulocytes
(or both), or from differing proportions of cell types with
fixed methylation [11]. We introduced the lymphocyte/
granulocyte ratio in the regression models to account for





Mean methylation (%) SD of methylation
4.1 27.8 31.3 8.5
8.0 29.4 31.8 9.0
5.2 30.9 29.5 8.7
0.3 31.4 28.1 8.4
5.5 28.4 31.5 8.7
8.1 31.2 28.7 8.6
8.7 22.5 30.8 8.6
4.5 29.0 28.1 7.5
lucose metabolism; IGM: Impaired glucose metabolism; T2D: Type 2 diabetes.
Table 2 Association of PBL methylation with T2D status in EJP - multivariable logistic modeling
Model Dependent variable Number (cases,
non-cases)
Main effect odds ratio P-value Interaction odds ratio P-value
1 T2D + IGM (groups 1 + 2 vs. groups 3 + 4) 929 (461, 468) 0.979 0.014 NA NA
2 0.894 0.006 1.002 0.023
3 0.909 0.021 1.001 0.045
1 T2D (group 1 vs. group 4) 562 (267, 295) 0.982 0.142 NA NA
2 0.846 0.011 1.003 0.021
3 0.853 0.02 1.003 0.022
Model 1: Independent variables: continuous age, age2, methylation. Model 2: Independent variables: continuous age, age2, methylation, methylation × age
interaction. Model 3: Independent variables: continuous age, age2, methylation, methylation × age interaction, BMI, sex, lymphocyte to granulocyte ratio. Group 1:
Normal glucose metabolism (GM); Group 2: Borderline GM; Group 3: Impaired GM; Group 4: T2D; NA: Not applicable (i.e. no interaction term was introduced).
Figure 1 Methylation vs. age in T2D and T2D-free individuals
from the Ashkenazi Jewish and the EJP samples.
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in white blood cell composition.
In the comparison of the combined group of T2D and
IGM subjects vs. the normal and the borderline GM
subjects, methylation was significantly inversely associ-
ated with diabetes and IGM in the age adjusted model 1
(odds ratio (OR) = 0.979, P = 0.014). Introduction of the
interaction term of age and methylation (model 2)
further improved the fit. The main effect for methylation
(OR = 0.894, P = 0.006) indicates that for a 1 unit
increase in methylation, the odds of T2D and IGM
decrease by a factor of 0.894, whereas the interaction
term (OR = 1.002, P = 0.023) points to an attenuation of
the inverse association with increasing age, such that for
each 1 year increase in age, the odds ratio increases by a
factor of 1.002 toward the null value (and beyond).
Adjustment for the additional covariates (model 3) mod-
estly attenuated the association (main effect: OR = 0.909,
P = 0.021; interaction term: OR = 1.001, P = 0.045).
In the T2D vs. normal GM comparison, methylation
was inversely but not significantly associated with T2D
(OR = 0.982, P = 0.142) in model 1. Introduction of the
interaction term (model 2) significantly improved the
fit of the model (main effect for methylation: OR =
0.846, P = 0.011; interaction term: OR = 1.003, P = 0.021).
Addition of the possible confounding variables (model 3)
had little effect (main effect for methylation: OR = 0.853,
P = 0.020; interaction term: OR = 1.003, P = 0.022). The
weakening of the inverse association of methylation with
T2D with advancing age in this restricted comparison
tended to be larger than in the full sample.
In line with our previous report of no significant as-
sociation between methylation level and BMI among
AsJs or in the Jerusalem LRC cohort [11], the analysis
of the EJP sample revealed no association between
BMI and methylation level (Additional file 1: Figure
S1).
Taken together, these data indicate an inverse associ-
ation of PBL methylation level with T2D that is inde-
pendent of sex, BMI, and the lymphocyte to granulocyte
ratio, but weakens with increasing age.Methylation by age within T2D categories
We analyzed the cross-sectional association of methyla-
tion status by age within T2D categories. The curvilinear
age association appeared to differ between diabetic and
non-diabetic subjects: in the combined group of normal
and borderline GM EJPs, the methylation level was
relatively high up to age 50 and then sharply de-
creased (Figure 1). T2D and IGM subjects, in contrast,
were already hypomethylated at young ages. The methy-
lation status of the normal group intersected with the
diabetic group between ages 55 and 65. Thus, the methy-
lation differences that were apparent between the young
diabetic subjects and the normal GM group no longer
existed at the older ages. Of interest, the average age of
T2D onset reported for Arabs in Israel (57 years) [6] is
close to the age of the shift toward demethylation and
corresponds with the age of intersection between the
methylation levels of normal and diabetic subjects.
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We compared the association of methylation with T2D
status in the Israeli Jewish and Palestinian Arab popula-
tions. We have previously reported that non-diabetic
AsJs had higher methylation levels than diabetic patients
between ages 40 and 70 [11]. Here we analyzed the
methylation levels of 281 AsJ T2D patients aged 40 to
87 and 348 non-diabetic AsJ controls aged 10 to 92. The
methylation status of the diabetic and the non-diabetic
groups across the age range was very similar to that
observed in the EJP population sample (Table 1).
As in the EJPs, the methylation levels of non-diabetic
AsJs were relatively high at young ages and decreased
with age, particularly after age 65. In contrast, diabetic
AsJs were already hypomethylated at the young ages.
The methylation status of the normal and diabetic AsJ
groups intersected around age 73, and thus the methyla-
tion differences between diabetic and non-diabetic sub-
jects observed at the younger ages were no longer
evident in the older ages (Figure 1). As in the EJP popu-
lation, the average age of T2D onset (68 years among
Israeli Jews [6]) is just above the age of the shift toward
accelerated hypomethylation (65 years) and corresponds
with the age at which the methylation level of normal
subjects intersects with the methylation level of T2D
patients.
Across most of the age distribution, non-diabetic EJPs
were hypomethylated compared to their AsJ counter-
parts, suggestive of a mechanistic link between the earl-
ier hypomethylation of the EJPs and the higher T2D
prevalence typical of this population. Furthermore, ac-
celerated demethylation and the intersection with the
methylation level of T2D subjects occur about 10 years
earlier in the EJPs as compared to the AsJs, corre-
sponding with a similar earlier onset of T2D in this
population.Discussion
In this study, we demonstrated and confirmed the occur-
rence of T2D-related DNA methylation differences in
PBLs. Despite methodological differences between the
studies, the main findings of the original study in Israeli
Jews were replicated in a sample of urban Palestinian
Arabs. These findings include large between-individual
variation in methylation, modest but consistent hypome-
thylation of T2D vs. T2D-free individuals, similar effect
sizes, a similar dependence of this association on age
(such as attenuation of the association in the older age
groups), and independence of T2D-related methylation
from the effects of BMI, sex, and white blood cell
composition.
We have applied accepted T2D classification methods
and tested methylation differences between variousdisease groups. The results indicate significant differ-
ences independent of the classification method (Table 2).
Despite sharing similarities in their genetic back-
grounds [20,21], Palestinian Arab and Israeli Jewish pop-
ulations show extensive phenotypic differences including
health behaviors [22,6], cardiometabolic characteristics
including considerable differences in T2D occurrence
[23,6] and HDL-cholesterol concentrations [23], coronary
heart disease incidence [24] and mortality [25], and life
expectancy [26]. Considering these diverse phenotypes
and the different lifestyles of the populations from which
the samples were drawn, it is striking that FTO methyla-
tion is associated with T2D in both populations. These
findings suggest that hypomethylation of the FTO site is
a common marker of diabetes in PBLs rather than a
population-specific phenomenon, though examination of
more genetically diverse populations remains to be done.
A growing body of evidence indicates frequent asso-
ciations between DNA methylation levels of PBL and
other tissues and organs [27]. Disease-related methyla-
tion in PBLs might be due to the widespread influence
of polymorphic sequences on the methylation levels of
nearby sites [28-30]. Hence, if the alleles of a given
disease-associated polymorphic sequence differentially
affect methylation levels, they are expected to create a
disease-associated methylation pattern. Such sequence-
influenced methylation sites are common in the hu-
man genome [29] and were previously associated with
T2D in PBLs [31]. However, extensive sequencing of
DNA molecules containing both T2D-related methylation
and sequence variations revealed that the methylation site
we have analyzed is independently associated with dia-
betes [11]. Although cis effects of very distant sequences
or effects in trans cannot be ruled out, cis-sequence-influ-
enced methylation is unlikely to account for the observed
T2D-related methylation in blood. Alternative mecha-
nisms might include early development patterning of
inter-individual differences shared by disease-related and
unrelated tissues, or blood-based mechanisms. We have
tested and rejected the possibility of differential white
blood cell composition as a mechanism underlying
diabetes-related methylation. However, other blood-based
mechanisms are possible, including for example differen-
tial activity states of circulating PBLs between diabetic
and non-diabetic individuals. Further examination of the
PBL-differentiating site in T2D-related tissues may indi-
cate which one of the above possibilities holds.
The molecular basis underlying the large diversity in
the prevalence of T2D among human populations is
currently unclear, but genetic and environmental factors
are almost certainly both involved. The molecular basis
for the higher prevalence and earlier age of onset of
T2D in Arab populations is unknown. We observed
similar trends of decreasing methylation with age in
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were hypomethylated compared to Jews at all ages evalu-
ated and attained the average methylation level of T2D
individuals about 10 years earlier than Jews (Figure 1).
The interpretation of this difference is complex. We
suspect that the hypomethylation of the normal EJP
population sample is not attributable solely to genetic
differences between the populations but rather involves
environmental differences such as diet and lifestyle,
possibly as early as the intrauterine period. In turn,
these methylation differences may define, or be associ-
ated with, altered gene expression profiles. Given that
hypomethylation in PBLs distinguished young healthy
individuals who later become diabetic from those who
remained healthy during a 13-year follow-up [11], the
lower methylation levels of the EJPs might predispose
them to higher T2D risk.
Conclusions
This is the first reported epigenetic marker to be associ-
ated with T2D in an Arab population. DNA hypomethy-
lation in PBLs, which is greater among Arabs than
Ashkenazi Jews, signifies increased T2D risk. The associ-
ation between PBL hypomethylation and T2D varied by
age, suggesting differential patterns of methylation aging
in healthy and diabetic individuals and between ethnic
groups. We expect that more PBL methylation sites in
the genome may be additively associated with T2D risk.




The EJP study is a population-based, cross-sectional
study. We examined the DNA methylation of a single
CpG dinucleotide in DNA from peripheral white blood
cells in a sample of 929 Palestinians. This specific CpG
in an intron of the FTO gene (Chr16: 53,809,231-2;
hg19), which is not covered by any of the commercially
available DNA methylation analysis tools, was examined
by an assay we customized in our lab as described below.
The association between methylation levels and individ-
ual phenotypes, specifically T2D, was analyzed and
compared to similar analyses performed in a separate
case–control study of 629 Israelis of Ashkenazi Jewish
descent.
Subjects and population cohorts
1. The EJP sample of the Jerusalem Palestinian-Israeli
Risk Factor Study was described in detail
elsewhere [32]. Briefly, an age-sex-stratified
random sample of 2,000 Palestinian Arabs aged 25
to 77, residents of East Jerusalem, was drawn fromthe Israel national population registry (in which
EJPs with the legal status of permanent residents
of Israel are recorded). Of these 70.5% could be
located. After exclusion of those not meeting the
eligibility criteria (10.4%), 970 EJPs were examined
(response rate of 76.7% among those located), and
929 were successfully analyzed for methylation
levels. Participants were recruited between 2005
and 2008 at the St. Josef Hospital in East
Jerusalem for face-to-face interviews and clinical
measurements performed by trained personnel.
The interview included sociodemographic
characteristics and information about health
behaviors and health status. All subjects provided
signed informed consent. The study was approved
by the St. Josef Hospital and Hadassah Medical
Center Ethics (Helsinki) Committees and the Israel
Ministry of Health National Review Board for
Genetic Studies.
2. Participants in the cross-sectional case–control
study were Israeli residents of Jewish Ashkenazi
origin (four grandparents): T2D subjects (n = 281)
were ascertained by the Israel Diabetes Research
Group, were treated for T2D, and were at least
10 years post-diagnosed at the time of DNA
collection, as previously described [11]. The control
group (n = 348) comprised non-diabetic subjects
with parents free of diabetes that were drawn from
three sources: the Israel Diabetes Research Group
(n = 188), the Jerusalem Perinatal Study [33] (n = 96),
and people undergoing health screening
examinations at a hospital-based clinic (n = 64). In
contrast with a previous report that included
controls aged 40 to 70 years from these same
sources [11], here the age was unrestricted and
included subjects aged 11 to 92 years. DNA samples
obtained from peripheral white blood cells were
analyzed anonymously. All subjects provided signed
informed consent. The study was approved by the
Hadassah Medical Center Helsinki Review
Committee, the Shaare Zedek Medical Center
Helsinki Review Committee, and the Israeli National
Helsinki Committee for Genetic Studies.
Classification of T2D status
Diabetes classification was based on combinations of a
reported prior physician’s diagnosis, medication for dia-
betes, and fasting and 2 h post-challenge glucose levels
as follows:
Group 1. Normal glucose metabolism (NGM): (fasting
glucose (FG) < 100 mg/dl) and (2-h post 75 g oral
glucose challenge (2HG) < 140 mg/dl) and (no diabetes
diagnosis or treatment)
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(99 < FG < 110 mg/dl) and (2HG < 140 mg/dl) and
(no diabetes diagnosis or treatment)
Group 3. Impaired glucose metabolism (IGM): (109 <
FG < 126 mg/dl) or (140 ≤ 2HG <200 mg/dl) or (group
2 with a reported diabetes diagnosis but no treatment)
Group 4. Diabetes: (FG > 125 mg/dl) or (2HG >
199 mg/dl) or (diabetes treatment).
The AsJ study was a case–control study in which
patients previously diagnosed with T2D were recruited
from diabetes outpatient clinics and a control group of
diabetes-free individuals was assembled as described
above. T2D diagnosis by a physician was verified be-
fore inclusion in the study.
DNA methylation analysis
DNA samples were extracted from PBLs, treated with
bisulfite (EZ-DNA kit, Zymo Research, Irvine, CA,
USA) and polymerase chain reaction (PCR) amplified
using the forward primer 5′GATAGGTAGGTAGGTG
GATTTGAAATT and the reverse biotinylated primer
5′biotin-ACAACAACTAACTTAATAAACCCTCAAT.
The PCR products were purified, quantified, and se-
quenced on a PyroMark Q24 bench-top device (Qiagen,
Venlo, Limburg, the Netherlands) from the internal pri-
mer 5′GGTGGATTTGAAATTTTATATAGTA. All sam-
ples were coded and analyzed anonymously and blinded
as to their diabetes status through the DNA purification,
amplification, and methylation analysis steps.
Quality control
Analyses were performed in 96-well plates. Within- and
between-assay (plate) repeatability was assessed by repli-
cation of randomly selected samples as follows: Each 96-
well plate was assigned 90 study samples and 6 technical
replicates. Of these replicates, half were duplicates from
the study samples in the same 96-well plate and the
other half were duplicates from those in a separate plate.
Thus, replication included all analysis steps; half of the
replicates were included in the original plates (‘within’)
and half were assigned to other plates (‘between’). The
within-assay and between-assay coefficients of variation
were 5.0% and 7.8%, respectively. The within- and
between-assay intraclass correlation coefficients were
0.973 (95% CI 0.943 to 0.988) and 0.889 (95% CI 0.787
to 0.944), respectively (Additional file 2: Figure S2).
Statistical analyses
Logistic regression with diabetes status as the dependent
variable was used to adjust methylation levels for linear
and quadratic terms of age and subsequently also for
BMI, sex, and white blood cell composition. The effect
modification of the methylation-T2D association wasevaluated by introduction of a multiplication term of
linear age and methylation. The contribution of the
interaction term was assessed by the difference in the
log likelihood before and after introduction of the term.
All analyses presented satisfied the Hosmer-Lemeshow
test for goodness of fit.
Additional files
Additional file 1: Figure S1. Scatter plots showing the correlation
between methylation and BMI among EJP. A. All participants. B. T2D-free
participants from groups 1 and 2. C. IGM and T2D participants from
groups 3 and 4.
Additional file 2: Figure S2. Within and between plate reproducibility
of DNA methylation pyrosequencing. Samples were allocated randomly
to 96-well plates for bisulfite conversion, amplification and pyrosequencing
with technical replicates in each plate. Each 96-well plate contained three
within-plate replicates and three replicates from other 96-well plates. The
within-plate replicates (A) and between-plates replicates (B) correlation
coefficients (r) and coefficients of variation (CV) are shown.
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